Case-Based Learning: Fever During Targeted Cancer Therapy Without Infection

Abstract

Fever occurring during targeted cancer therapy is commonly presumed to represent infection, yet drug-related pyrexia, tumor inflammation, cytokine-mediated reactions, immune dysregulation, and cancer-associated fever may produce an indistinguishable initial presentation. This diagnostic overlap creates a high-stakes clinical problem: delayed antimicrobial treatment can be dangerous in an immunocompromised patient, whereas unnecessary antibiotics, hospitalization, treatment interruption, and invasive investigations may cause avoidable harm. A case-based approach is therefore essential. Clinicians should assess the timing of fever in relation to drug exposure, associated symptoms, hemodynamic status, blood counts, organ function, microbiological findings, tumor burden, and response to carefully supervised interventions. Targeted agents implicated in noninfectious fever include BRAF and MEK inhibitors, epidermal growth factor receptor inhibitors, monoclonal antibodies, antibody-drug conjugates, kinase inhibitors, and cellular or immune-directed therapies. Management requires immediate risk stratification, appropriate cultures and imaging, empiric antimicrobials when clinically indicated, and subsequent reassessment when evidence for infection remains weak. Recognition of characteristic drug-specific syndromes can support safe de-escalation and continuation or modification of anticancer therapy. This review summarizes the epidemiology, mechanisms, risk factors, clinical features, diagnostic strategy, treatment, emerging approaches, and guideline-informed principles for managing fever without an identifiable infection during targeted cancer treatment.

Introduction

Fever is one of the most frequent acute clinical findings in oncology. In patients receiving targeted therapy, it may signal bloodstream infection, neutropenic sepsis, pneumonia, urinary infection, catheter-related infection, or an opportunistic process. It may also be a treatment-related adverse event without microbial disease. The distinction is clinically important because modern targeted therapies have distinct toxicity profiles and may provoke inflammation through mechanisms that differ from conventional cytotoxic chemotherapy. A patient with metastatic melanoma receiving combined BRAF and MEK inhibition, for example, may develop recurrent high fever with rigors, hypotension, and gastrointestinal symptoms despite repeatedly negative cultures. Similar presentations can occur after monoclonal antibody infusion, kinase inhibition, or immune-directed treatment.

The appropriate response is neither reflexive reassurance nor automatic attribution to the drug. Initial fever in a patient with cancer must be treated as potentially infectious until a structured assessment demonstrates otherwise. The clinician must simultaneously stabilize the patient, obtain diagnostic specimens without delaying time-critical therapy, and examine the temporal and biological relationship between fever and anticancer treatment. Case-based reasoning is particularly useful because a single laboratory result rarely establishes the diagnosis. The most reliable conclusion generally emerges from serial evaluation, exclusion of plausible infection, symptom pattern, drug pharmacology, and response to withdrawal or reintroduction.

Epidemiology / Disease Burden

The reported frequency of noninfectious fever varies substantially according to the cancer type, treatment regimen, study definitions, and duration of follow-up. Pyrexia is particularly recognized with BRAF inhibitors, especially when combined with MEK inhibitors, and may lead to emergency assessment, temporary treatment interruption, or hospitalization. Infusion-related fever is also documented with therapeutic antibodies and antibody-drug conjugates. In patients exposed to immune-activating treatments, fever may accompany systemic inflammatory syndromes or organ-specific immune-related adverse events.

The burden extends beyond the fever itself. Unnecessary broad-spectrum antibiotics may promote antimicrobial resistance, Clostridioides difficile infection, drug toxicity, and disruption of the intestinal microbiome. Repeated admissions increase cost and reduce quality of life, while avoidable treatment interruptions may compromise oncologic disease control. Conversely, a false diagnosis of drug fever can delay therapy for a serious infection. Fever during targeted cancer therapy should therefore be viewed as a problem of competing risks, requiring both rapid safety measures and deliberate diagnostic refinement.

Pathophysiology

Fever results from elevation of the hypothalamic thermoregulatory set point, usually through prostaglandin E2 generated in response to inflammatory cytokines. Interleukin-1, interleukin-6, tumor necrosis factor, interferon signaling, and other mediators can produce chills, rigors, malaise, tachycardia, and temperature elevation without microbial invasion. Targeted agents may initiate these pathways through immune-cell activation, tumor-cell lysis, altered cytokine release, hypersensitivity, or pharmacologic effects on signaling pathways involved in inflammatory regulation.

BRAF and MEK inhibition can produce a characteristic pyrexia syndrome in which fever is associated with chills, dehydration, hypotension, rash, renal dysfunction, and occasionally hepatic or neurologic abnormalities. The mechanism is incompletely defined and may involve paradoxical pathway effects, host immune activation, and drug-drug interactions. Monoclonal antibodies may cause infusion reactions through complement activation or cytokine release, particularly during early exposures. Cellular therapies and potent immune agonists can cause cytokine release syndrome, in which fever may be the first manifestation and can progress to hypotension, hypoxia, coagulopathy, or organ dysfunction. Cancer-associated fever may also arise from cytokines produced by the tumor or host immune response, while tissue necrosis and rapid tumor response can intensify inflammatory signaling.

Risk Factors

Risk is influenced by the specific anticancer drug, combination therapy, dose intensity, treatment cycle, and prior exposure. Patients receiving combination BRAF and MEK inhibition are especially important to identify because pyrexia may recur after treatment resumption. Early infusion cycles, rapid dose escalation, and a history of drug hypersensitivity increase concern for treatment-related reactions. High tumor burden, extensive necrosis, bulky metastatic disease, and rapidly changing disease biology may increase inflammatory fever.

Infection risk remains high in patients with neutropenia, lymphopenia, mucosal disruption, indwelling vascular devices, recent hospitalization, corticosteroid exposure, organ dysfunction, or prior antimicrobial-resistant colonization. Renal or hepatic impairment can increase drug exposure and toxicity. A prior episode of uncomplicated drug fever supports, but does not prove, recurrence. Importantly, risk factors for noninfectious fever and infection frequently coexist; therefore, an apparent treatment-related pattern should never override clinical instability or objective evidence of infection.

Clinical Features

Noninfectious fever often begins within a recognizable interval after treatment initiation, infusion, dose change, or re-exposure. Drug-related pyrexia may be abrupt and accompanied by rigors, fatigue, myalgia, arthralgia, nausea, diarrhea, headache, or rash. Fever that resolves after holding the suspected agent and recurs after reintroduction is strongly suggestive, although rechallenge should be undertaken only when clinically justified. In contrast, persistent fever with progressive focal symptoms, worsening oxygenation, altered mental status, localized pain, or hemodynamic instability should maintain a high suspicion for infection or severe inflammatory toxicity.

Clinical overlap is substantial. Chills and hypotension can occur in both bacteremia and cytokine-mediated reactions. Neutropenia may be caused by the malignancy or treatment and does not establish infection. Procalcitonin may be lower in some noninfectious inflammatory states, but its performance is inconsistent in oncology and it should not be used as a solitary rule-out test. The pattern over time, serial examination, microbiology, organ function, and response to intervention are more informative than any isolated feature.

Diagnosis

Evaluation begins with airway, breathing, circulation, mental status, perfusion, and a complete medication timeline. Temperature should be confirmed using a reliable method, and the clinician should document the last doses of targeted therapy, corticosteroids, antipyretics, antimicrobials, and other potentially interacting medications. Blood cultures from peripheral sites and each clinically relevant catheter lumen should be obtained before antibiotics when this does not delay treatment. Complete blood count with differential, renal and hepatic profiles, lactate when indicated, urinalysis, and cultures guided by symptoms are appropriate initial studies.

Imaging should be directed by symptoms and examination, with chest imaging considered for respiratory complaints or unexplained persistent fever. Evaluation for catheter infection, skin and soft-tissue infection, gastrointestinal disease, urinary infection, and thrombosis should be individualized. Viral testing is relevant during community outbreaks, respiratory symptoms, or epidemiologic exposure. If fever persists, repeated assessment for occult infection, disease progression, thromboembolism, medication reaction, adrenal insufficiency, and immune-mediated organ toxicity is necessary.

The diagnosis of treatment-related fever is one of exclusion supported by a coherent clinical pattern. Useful evidence includes repeated negative cultures obtained appropriately, absence of a focal source, stable or improving physiology, temporal association with treatment, rapid improvement after withholding the agent, and recurrence on rechallenge. These findings should be interpreted cautiously because prior antibiotics, low microbial burden, or localized infection can produce false-negative cultures.

Treatment & Management

Patients who are unstable, neutropenic with suspected infection, or clinically septic require immediate empiric antimicrobial therapy according to local protocols, resistance patterns, allergy history, and organ function. Fluid resuscitation, oxygen, vasopressors, source control, and critical care consultation should not be delayed while investigating a possible drug reaction. Antipyretics may improve comfort but can obscure fever trends and should not replace diagnostic monitoring.

When the patient is stable and infection has been reasonably assessed, the suspected targeted agent is commonly withheld. Management of BRAF and MEK inhibitor-associated pyrexia often includes treatment interruption, hydration, correction of electrolyte abnormalities, and evaluation for renal, hepatic, or cardiovascular complications. After clinical recovery and a careful review of severity, therapy may be resumed at the same or reduced dose, sometimes with a modified schedule or prophylactic antipyretic strategy. Severe, recurrent, or organ-threatening reactions may require permanent discontinuation and selection of an alternative oncologic approach.

Infusion reactions require interruption of the infusion, assessment of severity, supportive care, and treatment with antihistamines, corticosteroids, bronchodilators, or emergency measures when indicated. Cytokine release syndrome should be graded using accepted institutional criteria and managed with prompt specialist involvement; severe cases may require an interleukin-6 pathway inhibitor, corticosteroids, vasopressors, and intensive monitoring. Corticosteroids should be used for defined inflammatory or immune-mediated indications, balancing symptom control against potential effects on infection risk and antitumor immunity. Antibiotic de-escalation is appropriate only after multidisciplinary review confirms clinical stability and sufficiently low infection probability.

Recent Advances / Emerging Therapies

Recent research has focused on identifying biomarkers that distinguish infection from sterile inflammation. Serial inflammatory profiles, cytokine panels, host-response gene signatures, cell-free microbial DNA, and integrated machine-learning models are under investigation. These tools may eventually support earlier antibiotic de-escalation, but most remain insufficiently validated for independent bedside decision-making. Pharmacovigilance databases and prospective oncology registries are also improving recognition of regimen-specific fever patterns.

Therapeutic advances include more precise grading and early intervention for cytokine release syndrome, standardized fever pathways embedded in electronic oncology systems, and individualized dose-interruption algorithms. Pharmacokinetic modeling may help identify patients at increased risk of recurrent pyrexia, while combination-design strategies aim to preserve antitumor efficacy and reduce inflammatory toxicity. Future studies should prioritize prospective definitions, standardized microbiological adjudication, patient-reported outcomes, and long-term assessment of whether treatment interruption affects cancer control.

Guideline Recommendations

Guideline-based care consistently emphasizes that fever in a patient receiving anticancer therapy should initially be managed as a potentially serious infection when clinical risk is significant. Antimicrobial timing should follow febrile-neutropenia and sepsis principles, with local antibiograms guiding drug selection. Cultures and focused diagnostic testing should be obtained promptly, and treatment should be adjusted when microbiological or clinical data become available.

For suspected drug fever, oncology, infectious disease, pharmacy, and critical care collaboration is valuable, particularly when the treatment has substantial antitumor benefit. The suspected agent should be held during significant symptoms, toxicity should be graded systematically, and organ dysfunction should trigger escalation. Rechallenge or desensitization should be considered only after risk-benefit assessment, documentation of the previous reaction, and a monitored plan. Discharge requires stable vital signs, reliable follow-up, clear return precautions, and confidence that serious infection or progressive inflammatory toxicity has been addressed.

Conclusion

Fever during targeted cancer therapy without an obvious infection is a diagnostic challenge in which both undertreatment and overtreatment carry meaningful consequences. The safest strategy combines immediate assessment for sepsis and organ-threatening inflammation with disciplined consideration of treatment-related pyrexia. Timing, drug-specific toxicity patterns, serial examinations, laboratory trends, microbiological results, and response to treatment interruption should guide the final judgment. Careful collaboration can reduce unnecessary antibiotics and hospitalizations while preserving timely treatment for occult infection. As targeted therapies become more complex, standardized fever pathways, validated biomarkers, and prospective evidence will be essential for delivering safer, more individualized oncology care.